| Literature DB >> 35836981 |
Juntao Tan1, Yuxin He2, Zhanbiao Li1, Qinghua Zhang3, Yanzhi Yang4, Qian Xu5,6,7, Xiaomei Xu8,9.
Abstract
Background: The International Normalized Ratio (INR) is significantly associated with Hepatic Encephalopathy (HE) in patients with liver cirrhosis. However, the dose-response relationship between continuous INR changes and HE risk has not been clearly defined. Thus, our goal was to explore the continuous relationship between HE and INR among patients hospitalized with liver cirrhosis and to evaluate the role of the INR as a risk factor for HE in these patients.Entities:
Keywords: dose-response; hepatic encephalopathy; international normalized ratio; liver cirrhosis; restricted cubic spline
Mesh:
Year: 2022 PMID: 35836981 PMCID: PMC9273778 DOI: 10.3389/fpubh.2022.919549
Source DB: PubMed Journal: Front Public Health ISSN: 2296-2565
Figure 1Flow of inclusions and exclusions.
Demographic and clinical characteristics of the study population.
|
|
|
|
|
|
|---|---|---|---|---|
| Gender ( | 0.092 | |||
| Male | 4,402 (70.25%) | 385 (73.47%) | 4,017 (69.96%) | |
| Female | 1,864 (29.95%) | 139 (26.53%) | 1,725 (30.04%) | |
| Age (IQR, years) | 56.00 (49.00, 67.00) | 58.00 (50.00, 67.00) | 56.00 (49.00, 66.00) | 0.003 |
| International normalized ratio ( | <0.001 | |||
| ≥1.5 | 2,418 (38.59%) | 355 (67.75%) | 2,063 (35.93%) | |
| <1.5 | 3,848 (61.41%) | 169 (32.25%) | 3,679 (64.07%) | |
| History of liver disease ( | 0.259 | |||
| Yes | 1,304 (20.81%) | 99 (18.89%) | 1,205 (20.99%) | |
| No | 4,962 (79.19%) | 425 (81.11%) | 4,537 (79.01%) | |
| Smoking status ( | 0.005 | |||
| Yes | 2,803 (44.73%) | 265 (50.57%) | 2,538 (44.20%) | |
| No | 3,463 (55.27%) | 259 (49.43%) | 3,204 (55.80%) | |
| Drinking status ( | 0.001 | |||
| Yes | 2,792 (44.56%) | 271 (51.72%) | 2,521 (43.90%) | |
| No | 3,474 (55.44%) | 253 (48.28%) | 3,221 (56.10%) | |
| Alcoholic liver disease ( | <0.001 | |||
| Yes | 873 (13.93%) | 129 (24.62%) | 744 (12.96%) | |
| No | 5,393 (86.07%) | 395 (75.38%) | 4,998 (87.04%) | |
| Chronic hepatitis C ( | 0.684 | |||
| Yes | 254 (4.05%) | 23 (4.39%) | 231 (4.02%) | |
| No | 6,012 (95.95%) | 501 (95.61%) | 5,511 (95.98%) | |
| Chronic hepatitis B ( | 0.226 | |||
| Yes | 3,885 (62.00%) | 312 (59.54%) | 3,573 (62.23%) | |
| No | 2,381 (38.00%) | 212 (40.46%) | 2,169 (37.77%) | |
| Autoimmune liver disease ( | 0.293 | |||
| Yes | 533 (8.51%) | 51 (9.73%) | 482 (8.39%) | |
| No | 5,733 (91.49%) | 473 (90.27%) | 5,260 (91.61%) | |
| TB (IQR, umol/l) | 31.70 (17.80, 84.33) | 68.40 (31.78, 185.00) | 30.00 (17.20, 76.58) | <0.001 |
| NEU% (IQR, %) | 68.44 (59.40, 76.93) | 73.70 (63.80, 81.46) | 68.00 (59.00, 76.51) | <0.001 |
| HB (IQR, g/L) | 108.00 (85.00, 127.00) | 101.00 (79.00, 120.00) | 109.00 (85.00, 128.00) | <0.001 |
| AST (IQR, IU/L) | 59.00 (34.00, 119.00) | 66.35 (41.00, 142.25) | 58.00 (33.00, 117.00) | <0.001 |
| Na+ (IQR, mmol/l) | 139.10 (136.20, 141.60) | 138.00 (133.98, 141.13) | 139.20 (136.50, 141.60) | <0.001 |
| K+ (IQR, mmol/l) | 3.85 (3.53, 4.17) | 3.87 (3.48, 4.32) | 3.85 (3.54, 4.16) | 0.223 |
| ALB (IQR, g/L) | 30.80 (27.00, 35.20) | 28.70 (25.68, 31.60) | 31.10 (27.10, 35.50) | <0.001 |
| LYM% (IQR, %) | 20.70 (13.82, 28.40) | 16.37 (10.02, 22.71) | 21.10 (14.30, 28.80) | <0.001 |
| SCr (IQR, umol/l) | 66.10 (55.40, 81.00) | 67.70 (56.80, 94.08) | 66.00 (55.30, 80.10) | <0.001 |
| RBC (IQR, × 1012/L) | 3.50 (2.87, 4.10) | 3.23 (2.71, 3.80) | 3.53 (2.89, 4.11) | <0.001 |
| ALT (IQR, IU/L) | 38.00 (22.00, 89.00) | 38.00 (23.40, 87.25) | 38.00 (22.00, 89.00) | 0.272 |
| WBC (IQR, × 109/L) | 4.42 (3.06, 6.43) | 5.04 (3.38, 8.09) | 4.35 (3.01, 6.30) | <0.001 |
TB, total bilirubin; NEU%, Neutrophil percentage; HB, Total hemoglobin; AST, aspartate aminotransferase; Na+, Serum sodium; K+, Serum potassium; ALB, Albumin; LYM%, Lymphocyte percentage; SCr, serum creatinine; RBC, Red blood cell; ALT, Alanine aminotransferase; WBC, white blood cell; IQR, interquartile range.
Logistic regression analysis of the association between the INR and HE.
|
|
|
| ||||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |
|
| ||||||
| INR < 1.5 | Ref (1.000) | / | Ref (1.000) | / | Ref (1.000) | / |
| INR ≥ 1.5 | 3.747 (3.098, 4.532) | <0.001 | 3.995 (3.290, 4.850) | <0.001 | 2.606 (2.072, 3.278) | <0.001 |
|
| ||||||
|
| ||||||
| INR < 1.5 | Ref (1.000) | / | Ref (1.000) | / | Ref (1.000) | / |
| INR ≥ 1.5 | 3.059 (2.071, 4.518) | <0.001 | 3.209 (2.160, 4.768) | <0.001 | 2.380 (1.504, 3.765) | <0.001 |
|
| ||||||
|
| ||||||
| INR < 1.5 | Ref (1.000) | / | Ref (1.000) | / | Ref (1.000) | / |
| INR ≥ 1.5 | 3.975 (3.185, 4.960) | <0.001 | 4.272 (3.416, 5.341) | <0.001 | 2.667 (2.043, 3.482) | <0.001 |
|
| ||||||
|
| ||||||
| INR < 1.5 | Ref (1.000) | / | Ref (1.000) | / | Ref (1.000) | / |
| INR 1.5 | 3.877 (2.946, 5.101) | <0.001 | 4.125 (3.117, 5.459) | <0.001 | 2.826 (2.037, 3.921) | <0.001 |
|
| ||||||
|
| ||||||
| INR < 1.5 | Ref (1.000) | / | Ref (1.000) | / | Ref (1.000) | / |
| INR ≥ 1.5 | 3.572 (2.736, 4.663) | <0.001 | 3.881 (2.961, 5.086) | <0.001 | 2.385 (1.729, 3.289) | <0.001 |
|
| ||||||
|
| ||||||
| INR < 1.5 | Ref (1.000) | / | Ref (1.000) | / | Ref (1.000) | |
| INR ≥ 1.5 | 3.607 (2.753, 4.728) | <0.001 | 3.865 (2.932, 5.096) | <0.001 | 2.691 (1.951, 3.712) | <0.001 |
|
| ||||||
|
| ||||||
| INR < 1.5 | Ref (1.000) | / | Ref (1.000) | / | Ref (1.000) | / |
| INR ≥ 1.5 | 3.781 (2.885, 4.955) | <0.001 | 4.125 (3.135, 5.427) | <0.001 | 2.512 (1.811, 3.484) | <0.001 |
Model.
Figure 2Association between the INR and HE risk based on restricted cubic spline model in total population.
Figure 3Association between the INR and HE risk based on restricted cubic spline model stratified by alcoholic liver disease (A) no; (B) yes.
Figure 4Association between the INR and HE risk based on restricted cubic spline model stratified by smoking status (A) no; (B) yes.
Figure 5Association between the INR and HE risk based on restricted cubic spline model stratified by drinking status (A) no; (B) yes.